Adherex Technologies (NASDAQ:FENC – Get Free Report) will likely be issuing its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to post earnings of $0.0960 per share and revenue of $18.87 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:30 AM ET.
Adherex Technologies (NASDAQ:FENC – Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.03. Adherex Technologies had a negative return on equity of 5.71% and a negative net margin of 6.09%. The business had revenue of $17.87 million for the quarter, compared to analysts’ expectations of $16.21 million. On average, analysts expect Adherex Technologies to post $0.28 EPS for the current fiscal year and $0.97 EPS for the next fiscal year.
Adherex Technologies Stock Performance
Shares of FENC opened at $10.58 on Wednesday. The stock has a 50 day simple moving average of $10.72 and a 200 day simple moving average of $9.31. Adherex Technologies has a 52-week low of $5.65 and a 52-week high of $13.25. The firm has a market capitalization of $372.63 million, a PE ratio of -81.38 and a beta of 1.29.
Analysts Set New Price Targets
FENC has been the topic of several research analyst reports. B. Riley Financial restated a “buy” rating and set a $18.00 target price (up from $16.00) on shares of Adherex Technologies in a report on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adherex Technologies in a research note on Thursday, October 15th. Wedbush upped their price target on shares of Adherex Technologies from $13.00 to $16.00 and gave the company an “outperform” rating in a report on Wednesday, August 12th. Finally, HC Wainwright reiterated a “buy” rating and issued a $16.00 price target on shares of Adherex Technologies in a report on Wednesday, September 9th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $17.00.
Read Our Latest Stock Report on FENC
Insider Activity
In other news, insider Pierre Sargis Sayad sold 12,000 shares of the company’s stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $12.18, for a total transaction of $146,160.00. Following the completion of the transaction, the insider directly owned 9,519 shares of the company’s stock, valued at $115,941.42. This represents a 55.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Robert Andrade sold 75,000 shares of the stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $11.78, for a total value of $883,500.00. Following the transaction, the chief financial officer owned 217,675 shares of the company’s stock, valued at approximately $2,564,211.50. The trade was a 25.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.73% of the stock is owned by corporate insiders.
Adherex Technologies Company Profile
Fennec Pharmaceuticals, Inc., formerly known as Adherex Technologies, is a biopharmaceutical company focused on developing and commercializing therapies for pediatric cancer. The company’s lead product is PEDMARK (sodium thiosulfate), a platinum-based chemotherapy protective agent intended to reduce the risk of cisplatin-induced ototoxicity, or hearing loss, in children with localized, non-metastatic solid tumors. PEDMARK received approval from the U.S. Food and Drug Administration in 2022. Fennec markets the product in the United States through its commercial operations and has pursued regulatory and commercialization opportunities in international markets.
Read More
- Five stocks we like better than Adherex Technologies
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Adherex Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adherex Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
